NEWS
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than traditional rhGH injections. This supports Lumos Pharma's plans for a Phase 3 trial. Results showed GH secretion increased from 0.19 to 0.36 μg/kg/12-hrs at 1.6 mg/kg/day dose and from 1.17 to 1.8 μg/kg/12-hrs for pulsatile GH. The data suggests a positive correlation between growth response and GH pulsatility patterns.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment